"10.1371_journal.pone.0150685","plos one","2016-03-07T00:00:00Z","József Prechl; Krisztián Papp; Zoltán Hérincs; Hajna Péterfy; Veronika Lóránd; Zoltán Szittner; Andone Estonba; Paolo Rovero; Ilaria Paolini; Jokin del Amo; Maria Uribarri; Maria Claudia Alcaro; Otsanda Ruiz-Larrañaga; Paola Migliorini; László Czirják","Diagnosticum Zrt, Budapest, Hungary; MTA-ELTE Immunology Research Group, Eötvös Loránd University, Budapest, Hungary; Department of Rheumatology and Immunology, Clinic Center, University of Pécs, Pécs, Hungary; Department of Genetics, Physical Anthropology and Animal Physiology, University of the Basque Country, Bilbao, Spain; Department of NeuroFarBa, University of Florence, Florence, Italy; Toscana Biomarkers, Siena, Italy; Progenika Biopharma S.A., a Grifols Company, Derio, Bizkaia, Spain; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy","Conceived and designed the experiments: PR IP MCA LC. Performed the experiments: KP ZH HP ZS AE PM. Analyzed the data: JP KP VL JDA MU. Contributed reagents/materials/analysis tools: PR. Wrote the paper: JP ORL KP LC. Recruited patients: PM VL LC.","József Prechl, Zoltán Hérincs and Hajna Péterfy are employed by Diagnosticum Zrt, Ilaria Paolini and Maria Claudia Alcaro by Toscana Biomarkers and Jokin Del Amo and Maria Uribarri by Progenika. Paolo Rovero and Paola Migliorini are shareholders of Toscana Biomarkers. József Prechl and Krisztián Papp are inventors of a patent for microarray-based monitoring of antigen specific complement activation (EP2047269B1), which is owned by Eötvös Loránd Unniversity and Hungarian Academy of Sciences and is licensed by Diagnosticum zrt. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2016","03","József Prechl","JP",15,TRUE,4,6,5,4,TRUE,TRUE,FALSE,0,NA,FALSE
